Pediatrix Medical Group, Inc. (MD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 350M 700M 1.1B Q1 '17: 835.6M Q2 '17: 842.9M Q3 '17: 869M Q4 '17: 910.8M Q1 '18: 852.6M Q2 '18: 865M Q3 '18: 848.8M Q4 '18: 888.4M Q1 '19: 851.2M Q2 '19: 561.2M Q3 '19: 454.9M Q4 '19: 458.6M Q1 '20: 441.2M Q2 '20: 415.4M Q3 '20: 460.6M Q4 '20: 416.6M Q1 '21: 446.8M Q2 '21: 473M Q3 '21: 492.9M Q4 '21: 498.5M Q1 '22: 482.2M Q2 '22: 486M Q3 '22: 489.9M Q4 '22: 513.8M Q1 '23: 491M Q2 '23: 500.6M Q3 '23: 506.6M Q4 '23: 496.4M Q1 '24: 495.1M Q2 '24: 504.3M Q3 '24: 511.2M Q4 '24: 502.4M Q1 '25: 458.4M Q2 '25: 468.8M Q3 '25: 492.9M Q4 '25: 493.8M Q1 '26: 476.2M Q2 '26: 487.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-180M -120M -60M 0 60M 120M 180M Q2 '16: 147.8M Q3 '16: 156.9M Q4 '16: 142.8M Q1 '17: 106M Q2 '17: 121.9M Q3 '17: 126.4M Q4 '17: 125.7M Q1 '18: 99.7M Q2 '18: 122.4M Q3 '18: 104.2M Q4 '18: 105.6M Q1 '19: 78.5M Q2 '19: 59.4M Q3 '19: 48.6M Q4 '19: 40.1M Q1 '20: 10.8M Q2 '20: 34.6M Q3 '20: 20.5M Q4 '20: 32.3M Q1 '21: 26.1M Q2 '21: 50M Q3 '21: 58.8M Q4 '21: 68M Q1 '22: 39.1M Q2 '22: 50.2M Q3 '22: 47.4M Q4 '22: 36M Q1 '23: 30M Q2 '23: 48.5M Q3 '23: 40.3M Q1 '24: 15.9M Q2 '24: -157.7M Q3 '24: 33.8M Q4 '24: 39.3M Q1 '25: 32.1M Q2 '25: 59.9M Q3 '25: 68.1M Q4 '25: 48.8M Q1 '26: 41.7M Q2 '26: 56.9M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Net Income Quarterly

-1.5B -1B -500M 0 500M 1B 1.5B Q2 '16: 82.4M Q3 '16: 96.5M Q4 '16: 78.1M Q1 '17: 54.7M Q2 '17: 63.7M Q3 '17: 65.9M Q4 '17: 136.1M Q1 '18: 63.4M Q2 '18: 79.4M Q3 '18: 65.6M Q4 '18: 60.2M Q1 '19: -242.9M Q2 '19: -8.2M Q3 '19: -1.3B Q4 '19: 9.3M Q1 '20: -18.7M Q2 '20: -672.4M Q3 '20: -41M Q4 '20: -64.3M Q1 '21: 17.6M Q2 '21: 35M Q3 '21: 30.8M Q4 '21: 47.5M Q1 '22: -21.2M Q2 '22: 27.1M Q3 '22: 30.7M Q4 '22: 29.7M Q1 '23: 14.2M Q2 '23: 28.3M Q3 '23: 21.4M Q1 '24: 4M Q2 '24: -153M Q3 '24: 19.4M Q4 '24: 30.5M Q1 '25: 20.7M Q2 '25: 39.3M Q3 '25: 71.7M Q4 '25: 33.7M Q1 '26: 29.6M Q2 '26: 39.8M Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q1 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-210M -140M -70M 0 70M 140M 210M Q3 '16: 196.1M Q4 '16: 130.9M Q1 '17: -21.8M Q2 '17: 137.6M Q3 '17: 199.9M Q4 '17: 195.6M Q1 '18: -113.6M Q2 '18: 135.2M Q3 '18: 140.7M Q4 '18: 151.4M Q1 '19: -56.8M Q2 '19: 120M Q3 '19: 159.2M Q4 '19: 135.3M Q1 '20: -141.9M Q2 '20: 188.4M Q3 '20: 169.9M Q4 '20: 82.2M Q1 '21: -82.2M Q2 '21: 53.6M Q3 '21: 61.1M Q4 '21: 75M Q1 '22: -97.5M Q2 '22: 82.4M Q3 '22: 83.3M Q4 '22: 98.7M Q1 '23: -100.9M Q2 '23: 89.1M Q3 '23: 79.9M Q4 '23: 69.2M Q1 '24: -125.2M Q2 '24: 107M Q3 '24: 91.8M Q4 '24: 133M Q1 '25: -117.5M Q2 '25: 137.2M Q3 '25: 137.3M Q4 '25: 114.1M Q1 '26: -129.8M Q2 '26: 125.3M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow Quarterly

-210M -140M -70M 0 70M 140M 210M Q1 '16: -43.5M Q2 '16: 141M Q3 '16: 186.9M Q4 '16: 120.1M Q1 '17: -33.5M Q2 '17: 127.4M Q3 '17: 189.9M Q1 '18: -122.1M Q2 '18: 125.4M Q3 '18: 134.2M Q1 '19: -62.6M Q2 '19: 109.9M Q3 '19: 158.1M Q4 '19: 130.9M Q1 '20: -151.7M Q2 '20: 181.3M Q3 '20: 165M Q4 '20: 75.3M Q1 '21: -91.2M Q2 '21: 44.1M Q3 '21: 50.6M Q4 '21: 71.9M Q1 '22: -104.6M Q2 '22: 75.8M Q3 '22: 76.4M Q4 '22: 89.6M Q1 '23: -107.9M Q2 '23: 80.9M Q3 '23: 70.8M Q4 '23: 60.2M Q1 '24: -130.6M Q2 '24: 100M Q3 '24: 85.5M Q4 '24: 129.6M Q1 '25: -120.8M Q2 '25: 132.7M Q3 '25: 131.9M Q4 '25: 108.8M Q1 '26: -136.1M Q2 '26: 123.9M Q1 '17 Q3 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '15: 93.5M Q3 '15: 93.6M Q4 '15: 93.5M Q1 '16: 93.1M Q2 '16: 92.9M Q3 '16: 93.1M Q4 '16: 93.3M Q1 '17: 93.1M Q2 '17: 92.8M Q3 '17: 92.9M Q4 '17: 93.2M Q1 '18: 93.5M Q2 '18: 93.5M Q3 '18: 91.4M Q4 '18: 88.3M Q1 '19: 86.5M Q2 '19: 83.7M Q3 '19: 82.9M Q4 '19: 83.3M Q1 '20: 82.8M Q2 '20: 83.7M Q3 '20: 83.9M Q4 '20: 85.1M Q1 '21: 85.5M Q2 '21: 85.9M Q3 '21: 86.1M Q1 '22: 85.4M Q2 '22: 85.6M Q3 '22: 82.8M Q1 '23: 82.3M Q2 '23: 82.7M Q3 '23: 83M Q1 '24: 83.3M Q2 '24: 83.3M Q3 '24: 84.5M Q1 '25: 85.4M Q2 '25: 85.5M Q3 '25: 85.6M Q1 '26: 83.1M Q2 '26: 81.4M Q2 '16 Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-24.00 -16.00 -8.00 0.00 8.00 16.00 24.00 Q3 '15: 3.48 Q4 '15: 3.58 Q1 '16: 3.59 Q2 '16: 3.58 Q3 '16: 3.65 Q4 '16: 3.50 Q1 '17: 3.36 Q2 '17: 3.16 Q3 '17: 2.83 Q4 '17: 3.45 Q1 '18: 3.54 Q2 '18: 3.70 Q3 '18: 3.71 Q4 '18: 2.93 Q1 '19: -0.56 Q2 '19: -1.51 Q3 '19: -17.38 Q4 '19: -17.95 Q1 '20: -15.36 Q2 '20: -23.29 Q3 '20: -8.63 Q4 '20: -9.50 Q1 '21: -9.07 Q2 '21: -0.63 Q3 '21: 0.22 Q4 '21: 1.54 Q1 '22: 1.08 Q2 '22: 0.99 Q3 '22: 1.00 Q4 '22: 0.80 Q1 '23: 1.22 Q2 '23: 1.24 Q3 '23: 1.13 Q4 '24: -1.19 Q1 '25: -1.00 Q2 '25: 1.30 Q3 '25: 1.91 Q4 '25: 1.94 Q1 '26: 2.06 Q2 '26: 2.09 Q3 '16 Q4 '17 Q1 '19 Q2 '20 Q3 '21 Q4 '22 Q1 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.